Johnson & Johnson plans to conduct a late-stage study of the company’s investigational vaccine for Human Immunodeficiency Virus (HIV) in several countries across the Americas and Europe, including the United States.
South Africa’s Biovac Institute will start local production of Sanofi’s Hexaxim vaccine during 2020 and Pfizer’s anti-pneumonia Prevnar 13 vaccine in 2021.
Trust in vaccines – one of the world’s most effective and widely used medical products – is highest in poorer countries but weaker in wealthier ones where skepticism has allowed outbreaks of diseases such as measles to persist, a global study found.
VBI Vaccines Inc. said a late-stage study testing the company’s hepatitis B vaccine against GlaxoSmithKline’s Engerix-B met the main goals.
Scientists studying a bacterium that causes scarlet fever, severe sore throat and a form of heart disease are developing a vaccine that could prevent hundred of thousands of infections a year.
Dynavax CEO Eddie Gray will step down from his role on Aug. 1, 2019, as the Bay Area company undergoes restructuring to move away from immuno-oncology and prioritize the vaccine business.
GlaxoSmithKline will change incentives for sales representatives in some countries as the British drugmaker looks to retain talent.
Cambridge, Mass.-based Moderna announced the publication of results from two Phase I clinical trials of mRNA vaccines against two strains of influenza, H10N8 and H7N0.
Merck & Co.’s investigational 15-valent pneumococcal conjugate vaccine was “noninferior” to a currently available 13-valent pneumococcal conjugate vaccine in healthy babies 6 to 12 weeks of age.
In GlaxoSmithKline’s first-quarter 2019 report was an announcement that the global pharma giant cut the development of two vaccine programs – one for strep pneumonia and the other for a universal flu vaccine.